Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Niagen Bioscience IncNASDAQ: NAGE

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 79.92M shares rose 2.7% year over year, ahead of the +1.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.7% holds above the trailing-twelve-month pace of +1.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
79.92M+1.2% QoQ
Last fiscal yearDec 2025
79.18M-7.3% YoY
LTMMar 2026
82.42M+1.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.7%——
1 year-7.3%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
79.18M USD
Year-over-year change
-7.3%
4-year CAGR
+4.2%

Weighted Avg Shares vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's LTM Mar 2026 weighted avg shares of 82.42M shares is the 3rd highest of the 10 companies compared; the peer median is 53.8M shares.
  • Its year-over-year change of +1.7% is the 7th highest of 9, against a peer median of +8.0%.
  • Over three fiscal years its annual growth of +4.7% compares with a peer median of +12.9%.
NAGE Competitors Peer median
Weighted Avg Shares for NAGE and competitors
Company Period LTM YoY 3-year CAGR
AKBAAkebia Therapeutics, Inc.LTM Mar 2026264.94M +21.2%+12.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
NAGENiagen Bioscience IncLTM Mar 202682.42M +1.7%+4.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
ZVRAZevra Therapeutics, Inc.LTM Mar 202656.11M +13.7%+17.1%
PRTAProthena Corporation plcLTM Mar 202653.8M -0.0%+4.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202552.2M ——
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
KROSKeros Therapeutics, Inc.LTM Mar 202638.92M +1.7%+13.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
Peer median (excluding NAGE) 53.8M+8.0%+12.9%

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue67.45M72.05M83.57M99.6M129.42M
Cost of Revenue25.96M29.25M32.79M38.01M46.23M
Gross Profit41.49M42.8M50.78M61.59M83.19M
Gross Margin61.5%59.4%60.8%61.8%64.3%
Research & Development3.83M4.83M4.96M6.02M6.33M
Selling, General & Admin64.73M56.6M51.42M47.84M62.56M
Operating Expenses68.56M61.43M56.38M53.86M68.89M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
EBITDA(25.45M)(14.66M)(3.23M)10.34M19.64M
EBITDA Margin-37.7%-20.3%-3.9%10.4%15.2%
Operating Income(27.07M)(18.63M)(5.6M)7.73M14.3M
Operating Margin-40.1%-25.9%-6.7%7.8%11.0%
Interest Income03K661K1.13M2.13M
Interest Expense55K0000
Other Income / Expenses(55K)2.09M661K1.13M3.9M
Income Before Tax(27.13M)(16.54M)(4.94M)8.86M18.19M
Pre-Tax Margin-40.2%-23.0%-5.9%8.9%14.1%
Income Tax Expense000305K810K
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Net Margin-40.2%-23.0%-5.9%8.6%13.4%
EPS (Basic)(0.40)(0.24)(0.07)0.100.22
EPS (Diluted)(0.40)(0.24)(0.07)0.110.20
Weighted Avg Shares67.19M68.92M70.54M85.42M79.18M
Weighted Avg Shares (Diluted)67.19M69.73M74.99M79.72M85.44M

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.